JNJ
Johnson & JohnsonPrice & Indicators
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted Net Earnings non-GAAP | $6,009M | Q4 2025 | — |
| Free Cash Flow non-GAAP | $19,700M | Full Year 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Drug Manufacturers - General — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
JNJ
this stock
Johnson & Johnson
|
$633.19B | +27.8% | +6.0% | 30.5 | 1.1% |
|
LLY
ELI LILLY & Co
|
$1.13T | +11.9% | +44.7% | 42.6 | 1.0% |
|
ABBV
AbbVie Inc.
|
$450.11B | +12.4% | +8.6% | 125.5 | 1.3% |
|
MRK
Merck & Co., Inc.
|
$313.12B | +21.3% | +1.4% | 35.7 | 1.2% |
|
NVS
Novartis AG
|
$296.69B | +16.2% | — | — | 0.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| JNJ | +7.4% | +17.8% | +28.5% | +3.6% | +27.8% |
| SPY | +1.4% | -1.3% | +8.0% | -0.3% | +9.2% |
| vs SPY | +6.0% | +19.1% | +20.5% | +3.8% | +18.6% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.